Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by James Investment Research Inc.

James Investment Research Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 13.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,172 shares of the medical research company’s stock after selling 1,368 shares during the period. James Investment Research Inc.’s holdings in Thermo Fisher Scientific were worth $5,417,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Widmann Financial Services Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $26,000. Mystic Asset Management Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Lee Financial Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $32,000. Costello Asset Management INC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $33,000. Finally, Sumitomo Mitsui Financial Group Inc. increased its holdings in Thermo Fisher Scientific by 141.7% during the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company’s stock worth $38,000 after purchasing an additional 34 shares during the period. 87.48% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:TMO traded up $4.99 during mid-day trading on Monday, reaching $548.27. 37,954 shares of the stock were exchanged, compared to its average volume of 1,545,514. The company has a 50 day simple moving average of $539.82 and a 200-day simple moving average of $569.47. The stock has a market capitalization of $214.63 billion, a P/E ratio of 28.59, a P/E/G ratio of 1.86 and a beta of 0.82. The company has a quick ratio of 1.10, a current ratio of 1.56 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $497.83 and a 1 year high of $672.34.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.17 by $1.08. The firm had revenue of $11.82 billion for the quarter, compared to the consensus estimate of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted $7.21 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 15th. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, June 14th. This represents a $1.20 dividend on an annualized basis and a yield of 0.22%. Thermo Fisher Scientific’s payout ratio is 6.26%.

Several equities research analysts have weighed in on TMO shares. StockNews.com assumed coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $605.00 to $525.00 in a report on Monday, April 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $658.92.

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 17,150 shares of the stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following the completion of the sale, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at approximately $8,640,111.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Debora L. Spar sold 200 shares of the firm’s stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $544.36, for a total value of $108,872.00. Following the completion of the sale, the director now directly owns 810 shares of the company’s stock, valued at $440,931.60. The disclosure for this sale can be found here. Insiders have sold a total of 42,561 shares of company stock valued at $23,557,413 over the last ninety days. 0.43% of the stock is owned by insiders.

About Thermo Fisher Scientific (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.